-
64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer
NCT06298916 ·
Phase: Phase 1, Phase 2 ·
Ages: 15 Years and older ·
Sex: All (male and female) · 10 locations
-
A Beta-only IL-2 ImmunoTherapY Study
NCT05086692 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 27 locations
-
A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors
NCT06043466 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
A First-in-Human Escalation and Expansion Study of Patients With Advanced Solid Tumors
NCT06783569 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors
NCT06508307 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 2 locations
-
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT06586957 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 38 locations
-
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid Tumors
NCT06500052 ·
Phase: Phase 1 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT03526835 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 54 locations
-
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
NCT06999187 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
A Study of MGC026 in Participants With Advanced Solid Tumors
NCT06242470 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 36 locations
-
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors
NCT07066657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 42 locations
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
NCT06943521 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 18 locations
-
A Study of NX-1607 in Adults With Advanced Malignancies
NCT05107674 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 17 locations
-
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
NCT06395519 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 28 locations
-
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT05208762 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 62 locations
-
A Study of SHY-ONC6, a Novel Proteasome Inhibitor, in Adults With Advanced or Metastatic Solid Tumors
NCT07705334 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 12 locations
-
A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer
NCT07227168 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
AB122 Platform Study
NCT04999761 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 9 locations
-
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
NCT03190941 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 72 Years ·
Sex: All (male and female) · 2 locations
-
Autologous and Allogeneic Whole Cell Cancer Vaccine for Metastatic Tumors
NCT00722228 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
NCT03740256 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
NCT06006390 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 12 locations
-
CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors
NCT07179692 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies
NCT03539822 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors
NCT06126406 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
NCT06010862 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
NCT06337084 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors
NCT07517198 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT06239194 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
NCT06617169 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT02584244 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
GAIA-102 Intraperitoneal Administration in Patients With Advanced Gastrointestinal Cancer of Microsatellite Stable With Malignant Ascites
NCT05438459 ·
Phase: Phase 1, Phase 2 ·
Ages: 20 Years and older ·
Sex: All (male and female) · 1 location
-
IDOV-Immune for Advanced Solid Tumors
NCT06910657 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 10 locations
-
IKS014 in Advanced Solid Tumors That Express HER2
NCT05872295 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 13 locations
-
KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT05483491 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Lead-212 PSV359 Therapy for Patients With Solid Tumors
NCT06710756 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 22 locations
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 17 locations
-
Personalized DC Vaccine for Postoperative Cancer
NCT04147078 ·
Phase: Phase 1 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female) · 2 locations
-
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
NCT07529808 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
NCT07151040 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 4 locations
-
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT06047379 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 7 locations
-
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
NCT06005493 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 25 locations
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT04282044 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 6 locations
-
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT04198766 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 42 locations
-
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
NCT05427487 ·
Phase: Phase 1 ·
Ages: 18 Years to 85 Years ·
Sex: All (male and female) · 3 locations
-
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 15 locations
-
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
NCT04900818 ·
Phase: Phase 1 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 21 locations
-
Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors
NCT05187338 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 3 locations
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
NCT07432633 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 1 location